CDT Equity (CDT) Other Accumulated Expenses (2023 - 2026)
CDT Equity's (CDT) quarterly Other Accumulated Expenses came in at $786000.0 in Q1 2026, down 24.78% YoY from $1.0 million in Q1 2025, and up 46.1% on a QoQ basis from $538000.0 in Q4 2025.
CDT Equity (CDT) Other Accumulated Expenses (2023 - 2026) Analysis & Trends
CDT Equity (CDT) has 4 years of Other Accumulated Expenses data on file, last reported at $786000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 24.78% year-over-year to $786000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $786000.0 (down 24.78% YoY) and the FY2025 annual result came in at $538000.0, down 72.59% from the prior year.
- Other Accumulated Expenses grew to $786000.0 in Q1 2026, from $538000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.0 million in Q4 2024 to a low of $538000.0 in Q4 2025.
- A 4-year average of $1.1 million and a median of $915500.0 in 2025 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses surged 226.62% — and 2025, when it slumped 72.59%.
- Tracing CDT's Other Accumulated Expenses over 4 years: stood at $601000.0 in 2023, then surged by 226.62% to $2.0 million in 2024, then sank by 72.59% to $538000.0 in 2025, then jumped by 46.1% to $786000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $786000.0 (Q1 2026), $538000.0 (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 802,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Dec 31, 2025 | 538,000.00 |
| Sep 30, 2025 | 1.79 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 665,000.00 |
| Mar 31, 2024 | 743,000.00 |
| Dec 31, 2023 | 601,000.00 |